Oct-AAVP-TNF(Oct-AAVP-TNF) - 药物靶点：SSTR2 x TNF_在研适应症：胰腺神经内分泌肿瘤_专利_临床

概要

基本信息

药物类型

基因疗法

别名-

靶点

SSTR2 x TNF

作用机制

SSTR2拮抗剂(生长抑素受体2拮抗剂)、TNF抑制剂(肿瘤坏死因子抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [1]

在研适应症

胰腺神经内分泌肿瘤

非在研适应症-

原研机构

The University of New Mexico

在研机构

The University of New Mexico

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Oct-AAVP-TNF 相关的临床结果

登录后查看更多信息

100 项与 Oct-AAVP-TNF 相关的转化医学

登录后查看更多信息

100 项与 Oct-AAVP-TNF 相关的专利（医药）

登录后查看更多信息

1

项与 Oct-AAVP-TNF 相关的文献（医药）

2016-03-01·Proceedings of the National Academy of Sciences

AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas

Article

作者: Sidman, Richard L. ; Cui, Min-Hui ; Smith, Tracey L. ; Sanchez Claros, Carmen ; Gelovani, Juri G. ; Branch, Craig A. ; Cardó-Vila, Marina ; Adem, Asha ; Pasqualini, Renata ; Libutti, Steven K. ; Yuan, Ziqiang ; Arap, Wadih

SignificanceThere are literally thousands of biologically active, clinically relevant peptide motifs in mammalian species. Surprisingly, however, despite this abundance of potential peptide reagents for ligand-directed delivery, applications for targeted gene therapy are generally lacking. Here we used a hybrid AAV/phage (AAVP) vector for octreotide ligand-directed therapeutic gene delivery to pancreatic neuroendocrine tumors in a transgenic mouse model that faithfully recapitulates the cognate human disease. This platform is readily available for a translational clinical trial. In a broader context, this proof-of-concept work establishes a unique targeting paradigm in which existing ligand/receptors may be exploited in nature while minimizing or eliminating several rate-limiting steps of conventional phage display library selection that require cumbersome experimental discovery work.

100 项与 Oct-AAVP-TNF 相关的药物交易

登录后查看更多信息